Cannell Capital LLC Grows Stock Holdings in Eton Pharmaceuticals, Inc. $ETON

Cannell Capital LLC lifted its stake in shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON) by 17.3% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 455,405 shares of the company’s stock after acquiring an additional 67,230 shares during the quarter. Eton Pharmaceuticals makes up approximately 1.5% of Cannell Capital LLC’s holdings, making the stock its 11th biggest holding. Cannell Capital LLC’s holdings in Eton Pharmaceuticals were worth $9,896,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. State of Alaska Department of Revenue purchased a new stake in shares of Eton Pharmaceuticals in the third quarter valued at approximately $30,000. Ameritas Investment Partners Inc. purchased a new position in Eton Pharmaceuticals during the 2nd quarter worth $37,000. Legal & General Group Plc purchased a new position in Eton Pharmaceuticals during the 2nd quarter worth $41,000. Police & Firemen s Retirement System of New Jersey bought a new stake in Eton Pharmaceuticals during the 2nd quarter valued at $87,000. Finally, New York State Common Retirement Fund bought a new stake in Eton Pharmaceuticals during the 2nd quarter valued at $115,000. Institutional investors own 27.86% of the company’s stock.

Analyst Upgrades and Downgrades

ETON has been the topic of a number of recent research reports. Craig Hallum increased their price target on Eton Pharmaceuticals from $29.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday, March 3rd. HC Wainwright lifted their price objective on Eton Pharmaceuticals from $35.00 to $37.00 and gave the company a “buy” rating in a report on Monday, March 2nd. Zacks Research raised shares of Eton Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Thursday, January 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research report on Thursday, January 22nd. Finally, Wall Street Zen cut shares of Eton Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, December 13th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $31.00.

Eton Pharmaceuticals Stock Down 0.5%

Shares of NASDAQ ETON opened at $18.93 on Friday. Eton Pharmaceuticals, Inc. has a 12-month low of $11.09 and a 12-month high of $23.00. The stock’s fifty day simple moving average is $16.36 and its two-hundred day simple moving average is $17.28. The stock has a market capitalization of $507.70 million, a PE ratio of -75.72 and a beta of 1.19. The company has a current ratio of 1.63, a quick ratio of 1.25 and a debt-to-equity ratio of 1.19.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.